CND Life Sciences
United States
- Scottsdale, Arizona
- 07/04/2023
- Seed
- $4,500,000
CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions. Operating a CLIA-certified laboratory in Scottsdale, AZ, CND launched the Syn-One Test® as the first commercially available test to detect, visualize, and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid in the confirmation of a synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF). Through analysis of three small in-office skin biopsies provided by a referring physician, CND offers a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases. The company has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field.
- Industry Medical and Diagnostic Laboratories
- Website https://cndlifesciences.com/
- LinkedIn https://www.linkedin.com/company/cnd-life-sciences/
Maritime Fusion | $4,500,000 | (Nov 25, 2025)
Opti | $20,000,000 | (Nov 25, 2025)
Cordance Medical | $8,000,000 | (Nov 25, 2025)
AI One | $7,000,000 | (Nov 25, 2025)
Redrob | $10,000,000 | (Nov 25, 2025)
Pibit.AI | $7,000,000 | (Nov 25, 2025)
Votre | $3,750,000 | (Nov 25, 2025)
Tidalwave | $22,000,000 | (Nov 25, 2025)
Relixir | $2,000,000 | (Nov 25, 2025)
Interface | $3,500,000 | (Nov 25, 2025)
Model ML | $75,000,000 | (Nov 25, 2025)
Mirantus Health | $6,338,062 | (Nov 25, 2025)